Search results
Results from the WOW.Com Content Network
Eli Lilly shares have risen 30% so far this year, and were trading down about 1% at $758.90. Shares of Danish drugmaker Novo Nordisk (NOVOb.CO) have risen 10.6% this year and were trading 3.5% ...
A four-week supply of 2.5-milligram (mg) vials is $399, and a four-week supply of 5-mg vials is $529, less than half the list price of other GLP-1 medicines for obesity, according to Eli Lilly.
Eli Lilly's stock rose 9% in premarket trading before the bell on Friday. The new decision comes after a lawsuit filed by compounders forced the FDA to announce it was reviewing its original ...
Diabetes treatment Mounjaro has been on the health regulator's shortage list since late 2022, while weight-loss drug Zepbound was added in April as demand far outstripped supply. The limited ...
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented remedies are winning approval from some regulators overseas, posing a ...
(Reuters) -Eli Lilly's weight-loss drug, Zepbound, drastically cut the risk of developing type 2 diabetes in overweight or obese pre-diabetic adults after three years of weekly injections, the ...
Knowing how Lilly is laying the groundwork for long-term sustained growth can help investors determine whether the stock is a good buy at the moment. 3 billion reasons to keep an eye on Lilly
The injectable drug, made by the pharmaceutical company Eli Lilly, has the active ingredient tirzepatide, which had been approved in May 2022 to treat type 2 diabetes under the name Mounjaro.